Side Effects Joe Rogan Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Joe Rogan Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Status: Confirmed. Rogan has repeatedly stated on The Joe Rogan Experience that he uses TRT under physician supervision.
  • Drug class: Exogenous testosterone (typically injectable testosterone cypionate, based on his public descriptions).
  • Additional compounds discussed: Human growth hormone (HGH), BPC-157, ipamorelin, and NAD+ (all publicly discussed on air, though specific current use of each is not always confirmed).
  • Key clinical source: FDA-approved prescribing information for testosterone cypionate; the Endocrine Society 2018 clinical practice guideline on testosterone therapy in men with hypogonadism.
  • Page focus: Mapping Rogan's publicly described side effects to the documented adverse-event profile in clinical literature.

The public record: what Rogan has actually said

Joe Rogan's disclosure of TRT use is not a single interview quote. It is a running, years-long public conversation. On episode after episode of The Joe Rogan Experience (the most-listened-to podcast on Spotify, with an estimated 14.5 million listeners per episode as of 2024), Rogan has stated plainly that he takes testosterone under medical supervision. He has described receiving injections, monitoring bloodwork, and adjusting protocols with his physician.

In conversations with guests like Dr. Andrew Huberman, Dr. Peter Attia, and Dr. Mark Gordon, Rogan has gone further. He has discussed specific side effects he experienced, his hematocrit readings, and the rationale for concurrent use of compounds like HGH and peptides. On a 2023 episode with Huberman, Rogan described donating blood to manage elevated red blood cell counts, a well-characterized consequence of exogenous testosterone. In earlier episodes, he referenced acne flare-ups and changes in sleep architecture as effects he attributed to TRT.

Rogan has also publicly discussed using BPC-157 for injury recovery and NAD+ infusions for general wellness. He has mentioned ipamorelin in the context of growth hormone secretagogue protocols. These disclosures happened on air, in his own words. None of them require speculation.

What Rogan has not publicly confirmed is his exact dosing, his specific testosterone formulation beyond general references to injections, or the full list of ancillary medications he may use (such as aromatase inhibitors or hCG). The HealthRX Medical Team treats those details as unknown.

Side effect #1: Polycythemia (elevated hematocrit)

Rogan has described on multiple episodes that his hematocrit levels rose on TRT and that he donates blood periodically to bring them down. This is one of the most predictable adverse effects of exogenous testosterone.

The FDA prescribing information for testosterone cypionate lists polycythemia as a common adverse reaction. The mechanism is straightforward: testosterone stimulates erythropoietin production in the kidneys, which drives increased red blood cell mass. A 2017 meta-analysis in The Lancet Diabetes & Endocrinology found that testosterone therapy increased hematocrit by a mean of 2.8 percentage points compared to placebo, with the rate of polycythemia (hematocrit >54%) reaching 5-18% depending on the study population and formulation (Fernández-Balsells et al., 2010).

The Endocrine Society guideline recommends checking hematocrit at baseline, at 3-6 months, then annually. If hematocrit exceeds 54%, the guideline recommends dose reduction, formulation change, or temporary cessation. Therapeutic phlebotomy (blood donation, as Rogan describes) is widely used in clinical practice, though it is not the guideline's first-line recommendation.

HealthRX Medical Team take: Rogan's public description of donating blood for high hematocrit is clinically plausible and consistent with a known, dose-dependent effect of TRT. The fact that he monitors this with bloodwork suggests active physician oversight. However, repeated phlebotomy without addressing the underlying dose may deplete iron stores over time, a consideration the Endocrine Society has flagged in supplementary guidance.

Side effect #2: Acne and skin changes

Rogan has referenced acne as a side effect he experienced, particularly earlier in his TRT use. Androgenic skin effects are among the most frequently reported adverse events in testosterone trials.

The FDA label lists acne under common adverse reactions. A pooled analysis of testosterone trials in the Journal of Clinical Endocrinology & Metabolism found acne or oily skin reported in 15-25% of men on TRT, with higher rates associated with supraphysiologic dosing or injectable formulations that produce peak-and-trough testosterone levels. The mechanism involves androgen receptor activation in sebaceous glands, increasing sebum production.

This side effect is generally dose-responsive. Men whose trough levels remain within the physiologic range (400-700 ng/dL) experience acne far less frequently than those with peak levels exceeding 1 to 000 ng/dL.

Side effect #3: Sleep architecture changes

Rogan has mentioned sleep disruptions in the context of TRT, though his comments on sleep are intertwined with discussions of other factors (training intensity, sauna use, caffeine timing). Separating the TRT signal from confounders is difficult based on public statements alone.

The clinical literature offers mixed evidence. Testosterone therapy can improve sleep quality in men with documented hypogonadism and concurrent sleep complaints, but it may also worsen obstructive sleep apnea (OSA). The FDA label carries a warning about sleep apnea, particularly in men with risk factors such as obesity or pre-existing airway compromise. A study in the Journal of the American Medical Association found that testosterone therapy modestly increased the apnea-hypopnea index in older men (Snyder et al., 2018).

HealthRX Medical Team take: Without knowing Rogan's sleep study data, we cannot attribute his reported sleep changes specifically to TRT. The clinical literature supports both improved subjective sleep quality in hypogonadal men and worsened sleep-disordered breathing. Any man on TRT who reports sleep disruption should undergo formal polysomnography.

The peptide and HGH overlay

Rogan's public protocol extends beyond testosterone alone. He has discussed using HGH, BPC-157, ipamorelin, and NAD+ in various podcast episodes. This matters for side-effect attribution because some effects men experience on multi-compound protocols get misattributed to testosterone when another agent is the more likely cause.

HGH, for example, is associated with fluid retention, joint stiffness, carpal tunnel syndrome, and insulin resistance (FDA prescribing information for somatropin). A man experiencing joint swelling or morning stiffness while taking both TRT and HGH might blame testosterone, when the growth hormone is the more probable driver.

BPC-157, a synthetic peptide derived from a gastric protein sequence, has no FDA approval and limited human trial data. Rogan has discussed using it for tendon and ligament recovery. The preclinical evidence in rodent models shows wound-healing and anti-inflammatory effects (Sikiric et al., 2018), but the human safety profile remains poorly characterized.

Ipamorelin, a growth hormone secretagogue, stimulates pulsatile GH release. Like BPC-157, it lacks FDA approval. It is used in some longevity-medicine clinics, and Rogan has mentioned it in the context of his overall protocol. Side effects in limited clinical data include transient headache and flushing.

HealthRX Medical Team take: When a public figure discusses a multi-compound protocol, listeners often focus on the most recognizable drug (testosterone) and attribute all effects to it. Clinically, the side-effect profile of a stack is not the sum of each drug's label. Interactions between testosterone, HGH, and peptides can produce effects (such as compounded fluid retention or changes in insulin sensitivity) that no single agent's prescribing information fully predicts. This is why physician-supervised bloodwork monitoring, which Rogan consistently advocates for, is not optional. It is the minimum standard of care.

Cardiovascular risk: the question Rogan hasn't addressed in detail

One side effect Rogan has not extensively discussed in public is the cardiovascular risk signal associated with TRT. The FDA required a boxed warning update in 2015 cautioning about possible increased risk of heart attack and stroke. The subsequent TRAVERSE trial, published in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism and pre-existing cardiovascular risk did not significantly increase the incidence of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months.

The TRAVERSE results were reassuring but not definitive. The trial excluded men under 45, men without cardiovascular risk factors, and men using supraphysiologic doses. Rogan, who began TRT in his 40s and has discussed using doses sufficient to maintain levels he describes as "high-normal," falls into a demographic space adjacent to, but not perfectly overlapping with, the TRAVERSE population.

HealthRX Medical Team take: The cardiovascular question remains the most clinically significant uncertainty for any long-term TRT user. The TRAVERSE trial reduced concern for men with established risk factors at replacement doses. But for men who have been on TRT for 10+ years, who may use higher doses, and who combine testosterone with HGH, the long-term cardiovascular data simply does not exist yet. Monitoring should include lipid panels, inflammatory markers (hsCRP), coronary calcium scoring at appropriate intervals, and serial hematocrit, as Rogan himself has described.

What this means for listeners

Rogan's influence on TRT adoption among men is difficult to overstate. His platform reaches millions, and his open discussion of testosterone therapy has contributed to a cultural shift in how men think about hormone optimization. The side effects he has described publicly are real, clinically documented, and consistent with the known adverse-event profile of exogenous testosterone.

The gap between Rogan's experience and the average listener's situation is significant. Rogan has described working with physicians, running comprehensive bloodwork panels, and adjusting protocols based on lab results. He has access to concierge medicine, frequent monitoring, and a network of longevity-focused clinicians. A listener who hears "I take testosterone and donate blood when my hematocrit goes up" and applies that logic without physician supervision faces substantially higher risk.

The Endocrine Society's 2018 guideline is unambiguous: testosterone therapy requires a confirmed diagnosis of hypogonadism (two morning total testosterone measurements below 300 ng/dL), a clinical indication, and ongoing monitoring including hematocrit, PSA, liver function, and lipids. "I want to feel better" is not a diagnostic criterion. "Joe Rogan does it" is not a clinical indication.

Frequently asked questions

›
›
›
›
›

References